The FDA extended the review period for the tinlarebant New Drug Application for Stargardt disease type 1 by three months, moving the PDUFA action date to May 12, 2027. If no major deficiencies are identified, the FDA plans to communicate proposed labeling requests by April 12, 2027.
BLTE · Belite Bio, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 66%
- Last earnings
- Nov 12, 2026
- Price history
- Apr 2022 to Nov 2026
Up next
Latest documents
Beelite Bio reported FDA acceptance of its NDA for TeneraBand with priority review, a February 12, 2027 put-to-fit date and no advisory committee. Q3 GAAP net loss was $30.3 million; cash, cash equivalents and U.S. Treasury bills totaled $774 million.
Belite Bio said FDA will not convene an advisory committee for tinlarebant’s STGD1 NDA, with a PDUFA target action date of February 12, 2027. It reported a $30.3 million third-quarter net loss and $271.3 million cash and equivalents as of September 30, 2026.
Belite Bio received Nasdaq approval to move its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest of the three Nasdaq tiers. Trading on the new market starts at the open on October 19, 2026, under the existing ticker BLTE.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLTE
this stock
Belite Bio, Inc
|
$5.17B | -20.4% | — | — | 3.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 20, 2026
- This year
- 13
The FDA extended the review period for the tinlarebant New Drug Application for Stargardt disease type 1 by three months, moving the PDUFA action date to May 12, 2027. If no major deficiencies are identified, the FDA plans to communicate proposed labeling requests by April 12, 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLTE | -22.5% | -13.5% | -5.6% | -17.7% | -20.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -13.9% | -4.3% | +3.6% | -9.0% | -21.5% |